China Climbs the Global Value Chain for Medical Devices

Mihir P. Torsekar

Abstract

This article discusses China’s transition towards higher-value-added segments of the medical device global value chain (GVC) as observed through changes in both the composition of foreign direct investment (FDI) and in the technological complexity of its medical device exports. The period under review is primarily 2003–17.
China Climbs the Medical Device Global Value Chain

Introduction

Global value chains (GVCs) refer to the iterative steps that transform a product from conception to its eventual placement in the market. More specifically, a GVC reflects the value-added contributions that are made at each stage of production. Activities in a GVC can be broadly categorized as low-value added (e.g., simple forms of manufacturing and assembly) or high-value added (e.g., research and development, more complex manufacturing, post-market services, etc.). Prior to 2009, China’s medical device industry mostly resided in the low-value added spectrum of the GVC. This was largely reflected in both the type of foreign direct investment (FDI) that the country attracted and the relative lack of sophistication of China’s medical device exports.

For example, during 2003–09, projects involving foreign investment into China’s medical device sector were primarily directed towards manufacturing—the lowest value-added segment of the GVC—while exports were predominantly composed of low-technology (tech) devices. However, during 2010–17, the composition of FDI shifted into high-value-added activities, which include research and development (R&D), sales, and post-sales services. At the same time, China’s medical device exports transitioned into mostly medium-to-high-tech categories.

GVC analysis often makes use of world input/output tables, which catalogue both the trade and the value-added contributions made at each stage of production. However, these data are not available for the medical device industry. Instead, this article relies exclusively on greenfield FDI data from the Financial Times service, fDi Intelligence, along with trade data from IHS Markit’s Global Trade Atlas to assess China’s ascent up the medical device GVC. Evidence for the validity of this approach is given in a brief literature review later on in this paper.

Global Industry Overview

Medical devices range in complexity from relatively unsophisticated goods, such as bandages and other hospital supplies, to high-tech capital goods, such as diagnostic equipment. Studies have listed four major product groupings, ranging from least to most sophisticated: (1) disposables (bandages, surgical gloves, and plastic syringes); (2) surgical and medical instruments (devices used in surgeries and cosmetic procedures); (3) therapeutics (includes implantable devices like hearing aids and prosthetics and non-implantable devices such as ventilators and infusion pumps); and (4) diagnostic equipment (capital equipment that is technologically complex) (figure 1).

---

4 GVCs refer to the iterative steps that transform a product from conception to a finished good. Further, a GVC reflects the value-added contributions at various stages of production. Timmer, User Guide to World Input-Output Database, 2015.
5 Also see Torsekar, “China’s Changing Medical Device Exports,” January 2018 for a discussion of how government policies and the domestic industry have contributed to these shifting exports.
6 Greenfield investments refer to new projects that are undertaken by a parent company. These projects can range from the erection of new manufacturing facilities to distribution centers, and headquarters.
China Climbs the Medical Device Global Value Chain

Figure 1: Medical device categories and their relative technological complexity

The production of global medical devices is largely led by firms headquartered in the United States which, during 2017, boasted 9 of the world’s top 15 producers and represented roughly one-quarter of global market share (table 1). Leading original equipment manufacturers (OEMs) of medical devices make a substantial portion of their sales in foreign markets. For example, U.S. medical device OEMs in recent years, have earned between 40 and 50 percent of their revenues outside the United States.⁷ Europe has accounted for roughly 30 percent of these sales. However, the rapidly growing healthcare markets in the Asia-Pacific region—especially in China—have attracted increasing levels of investment from OEMs, suggesting that these firms expect the region to generate significant future sales.⁸ From April 2009 through May 2017, the region captured the largest share of FDI for the medical device sector (figure 2). Every firm listed in table 1 has made investments in China.

---

⁸ Ibid.
China Climbs the Medical Device Global Value Chain

Table 1: The world’s top 15 medical device manufacturers in 2017 by revenue, headquarters, and 2015 market share

<table>
<thead>
<tr>
<th>Company</th>
<th>Headquartered</th>
<th>Revenue ($ bn)</th>
<th>Global Market Share (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medtronic</td>
<td>Ireland</td>
<td>28.8</td>
<td>8</td>
</tr>
<tr>
<td>Johnson &amp; Johnson</td>
<td>United States</td>
<td>25.1</td>
<td>6</td>
</tr>
<tr>
<td>Siemens Healthineers</td>
<td>Germany</td>
<td>15.2</td>
<td>3</td>
</tr>
<tr>
<td>Becton Dickinson</td>
<td>United States</td>
<td>12.5</td>
<td>3</td>
</tr>
<tr>
<td>Cardinal Health</td>
<td>United States</td>
<td>12.4</td>
<td>3</td>
</tr>
<tr>
<td>Phillips HealthTech</td>
<td>The Netherlands</td>
<td>12.4</td>
<td>3</td>
</tr>
<tr>
<td>Stryker</td>
<td>United States</td>
<td>11.3</td>
<td>3</td>
</tr>
<tr>
<td>Baxter</td>
<td>United States</td>
<td>10.2</td>
<td>2</td>
</tr>
<tr>
<td>Abbot Laboratories</td>
<td>United States</td>
<td>10.1</td>
<td>2</td>
</tr>
<tr>
<td>Boston Scientific</td>
<td>United States</td>
<td>8.4</td>
<td>2</td>
</tr>
<tr>
<td>Danaher</td>
<td>United States</td>
<td>7.8</td>
<td>2</td>
</tr>
<tr>
<td>Zimmer Biomet</td>
<td>United States</td>
<td>7.7</td>
<td>2</td>
</tr>
<tr>
<td>Essilor</td>
<td>France</td>
<td>7.5</td>
<td>2</td>
</tr>
<tr>
<td>B.Braun</td>
<td>Germany</td>
<td>6.8</td>
<td>2</td>
</tr>
<tr>
<td><strong>Top 15 totals</strong></td>
<td><strong>n/a</strong></td>
<td><strong>176.2</strong></td>
<td><strong>43</strong></td>
</tr>
</tbody>
</table>


Note: Market share data are presented for 2015, the most recent year for which these data were available.

Figure 2: Share of new FDI projects, by region, January 2009–August 2017

These investments reflect, in part, the growing healthcare markets within the Asia-Pacific region, which represent more than half of the world’s population and roughly one-quarter of the global medical device market.9 High urbanization rates10 and growing disposable income in countries such as China and India, coupled with an aging population in China in particular, are creating a sizable demand for devices of varying complexity, including cardiac pacemakers and orthopedic implants.

The Global Value Chain for Medical Devices

The GVC for medical devices can be roughly broken down into six distinct phases of production, ranging from high-value-added activities, such as research and development (R&D), to the lower-value-added segments, such as the manufacturing and assembly of components (figure 3). The range of value-added activities has been said to resemble a “smile,” where the highest-value-added activities are close to the producer and the consumer at the very beginning and end of the GVC, while the production stages that occur in the middle are considered the lowest-value-added segment.11

Figure 3: The global value chain (GVC) for medical devices

R&D is the highest value segment of the GVC for medical devices and accounts for an estimated 60 percent of the final cost of medical device production.12 This segment of the value chain includes product design, obtaining regulatory approval for sale in particular markets, and the determination of product pricing.13

As noted, manufacturing and assembly represent the lowest-value-added stages of the medical device GVC. As a result, much of the manufacturing-related FDI directed towards Asia largely reflects the low labor costs associated with this region.15 The activities related to this segment of the GVC include:

---

11 The smile curve was first suggested in 1992 when the founder of a Taiwanese technology company reportedly observed that the ends of the value chain were associated with higher-value-added contributions than was the middle. It has since been used as a model to interpret value-added contributions of countries and industries. Degain, Meng, and Wang, “Recent Trends in Global Trade,” 2017, 54.
12 Industry representative, interview by author, San Diego, CA, October 18, 2017.
13 Medical devices are commonly regulated according to a risk-based classification system; the stringency of a standard reflects its relative complexity and potential harm to consumers. The world’s leading medical device markets, (the United States, Japan, the European Union, and China) all use a similar classification system to regulate medical devices, though there are variations in the regulatory requirements across each market. The different regulatory regimes are reflected in the differences of time to market for various devices in these countries. For example, the European Union has the shortest approval time—on average—across all categories of devices among the leading markets. Torsekar, “U.S. Medical Devices,” June 2014; Emergo, “Compare the time,” 2017.
15 In recent years, for example, China’s labor rates were estimated to be from 60 to 80 percent less than those observed in the United States. Notably, these labor cost advantages have been eroding relative to other regional suppliers. Crawford, “Asia’s Continued Manufacturing Evolution,” May 10, 2012.
China Climbs the Medical Device Global Value Chain

- The production of components for low-tech products, such as the fabric used for mastectomy bras and the precision workings for metal stents.16
- The production of parts for medium- to high-tech products, including circuit boards and software for pacemakers and diagnostic equipment.

Many of these components often require the application of resins and coatings to prevent rusting and ensure proper functioning of the finished product.17

The three final stages of the medical device GVC (distribution, marketing and sales, and post-sales service) are considered high-value-added activities. Activities in this segment include coordination with the distributors or the end users to conduct sales. Low-tech products (disposables and surgical equipment) are generally marketed and sold in bulk to wholesale distributors, whereas high-tech products tend to be sold directly to hospital administrators or specialty care facilities.18 Post-sales services include the training and consulting activities that occur once a device (commonly high-tech equipment) has entered the market; they are intended to insure the proper use of the device.19

**FDI and GVCs: Presentation of Data**

As previously stated, because input/output data were not available for the medical device industry, this paper uses greenfield FDI data to determine China’s position on the medical device GVC. Evidence for the validity of this approach is provided in a literature review on the ways that FDI influences both GVC activity and the composition of a country’s exports (box 1).

---

18 Bamber and Gereffi, *Costa Rica*, August 2013
Box 1. Foreign Direct Investment (FDI), Global Value Chains (GVCs), and Export Composition: A Brief Literature Review

The role of FDI in influencing both a country’s contribution to global value chains and the composition of its exports has been explored in a number of recent publications. For example, the European Central Bank (2017) found an indirect association between policies that encourage FDI and a host economy’s participation in GVCs. The research also pointed to the role that foreign investors play in shaping a country’s exports. Further, the World Bank (2015) cited FDI as the principal means through which countries engage in GVCs.

More specifically, Amador and Cabral (2014) found that FDI plays a critical role in arranging GVCs operated by multinational corporations (MNCs). Nikolovová’s (2013) examination of data for the 27 countries then making up the European Union found a positive correlation between FDI growth at the sectoral level and demand for intermediate goods.

Other researchers have concluded that FDI plays an important role in reconfiguring a given country’s economic and export structure (Damijan, Kostevc, and Rojec, 2013). Further, Bajgar and Javorcik (2016) noted that FDI may translate into higher-value-added exports from domestic firms due to the strength of backward linkages, as local suppliers compete to produce high-quality parts to meet the needs of MNCs.

During 2003–17, greenfield foreign direct investment (FDI) in China’s medical device sector totaled $1.9 billion. The world’s largest medical device manufacturers contributed more than one-third of this total and more than one-quarter of the total number of projects.20 From 2003 to 2009, foreign investors were especially driven to supply China’s burgeoning medical device market, encouraged by the opportunity to achieve lower production costs.21 For this reason, investments during this time were largely oriented towards manufacturing. During 2010–17, however, the pattern of investment projects shifted away from low-value-added activities (manufacturing and assembly) and towards high-value-added segments (R&D, distribution, marketing and sales, and post-market services) (figure 4).

---

20 FDi Intelligence, October 13, 2017).
21 During 2003–07, the two most commonly cited motives for FDI were China’s market growth and low labor costs. FDi Intelligence (accessed October 13, 2017).
China Climbs the Medical Device Global Value Chain

Figure 4: FDI projects in China’s medical device sector during 2003–09 were concentrated in low-value added activities; this pattern reversed during 2010–17.

FDI into China’s medical device sector during 2003–17 were concentrated in two provinces (Guangdong and Jiangsu), as well as two municipalities (Beijing and Shanghai) in Eastern China (figure 5). Collectively, these destinations accounted for three-quarters of all of the sector’s FDI projects in the country and for $1.3 billion of the $1.9 billion of the capital investments into China over this period. Not surprisingly, a substantial amount of manufacturing for industries related to medical device production occurs at some of these locations, which have been identified as manufacturing clusters (table 2).

For example, some of the activities that occur at these locations are manufacturing for electronics and electrical equipment, as well as the establishment of centers for industrial machinery and information technology. These activities suggest that foreign OEMs operating in China may be able to acquire inputs from domestic producers (defined earlier as backward linkages). Moreover, these locations are associated with strong transportation networks, access to shipping ports, and the country’s greatest concentration of high-end hospitals.

In addition, China’s 2014 introduction of a policy aimed at supporting domestic innovation has especially benefitted companies operating in Beijing, Shanghai, Guangdong, Jiangsu, and Zheijiang. Collectively, these areas have accounted for 80 percent of all the devices that have been selected for expedited approvals under this policy.

---

22 Clusters, as defined by Michael E. Porter are geographically concentrated interconnected entities operating within a particular industry. Porter, “Clusters,” November-December 1998.
24 IBISWorld, Medical Device Manufacturing in China, July 2017, 17.
China Climbs the Medical Device Global Value Chain

Figure 5: Most FDI projects during 2003–17 have been aimed at Eastern China, especially Shanghai.

Table 2: China’s prominent manufacturing clusters

<table>
<thead>
<tr>
<th>Manufacturing cluster</th>
<th>Industries served</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beijing</td>
<td>Automotive, chemicals, pharmaceuticals, metals, industrial machinery, information technology</td>
</tr>
<tr>
<td>Changshu</td>
<td>Automotive, industrial machinery and parts, pharmaceuticals</td>
</tr>
<tr>
<td>Shanghai</td>
<td>Automotive, biotechnology, electronics and electrical equipment, transportation and logistics</td>
</tr>
<tr>
<td>Suzhou</td>
<td>Chemical and pharmaceutical, industrial machinery and parts, information technology</td>
</tr>
</tbody>
</table>


China’s Transition into High-Tech Exports

In addition to changing patterns of FDI, China’s rise along the medical device GVC is also reflected in the composition of the country’s medical device exports. For most of the past two decades, those exports were predominantly low-tech medical goods. During 2001–11, for example, disposable devices were China’s largest category of medical device exports, accounting for more than one-quarter of the sector’s overall exports over that period. However, by 2012, medium- to high-tech devices had emerged as China’s largest share of medical device exports (figure 6). Two categories have driven much of this transition: therapeutic devices have been...
China Climbs the Medical Device Global Value Chain

China’s largest medical device export category since 2012, while diagnostic equipment registered the highest growth rate of any of the remaining categories since 2001.

Figure 6: China’s medical device exports have transitioned from low-tech into medium-to high-tech during 2012–16.

Conclusion

During 2003–17, China gradually transitioned away from low-end segments of the medical device GVC, towards high-end activities. This shift is reflected in the types of FDI made during this time. For the first six years of this period, FDI was principally directed to manufacturing and assembly—the lowest value-added segments of the GVC. In contrast from 2009 through 2017, the majority of investments were geared towards R&D, distribution, marketing and sales, and post-market services; all of these activities are considered high-value added. This shift along the GVC has also been reflected in the changing technological complexity of China’s exports from low-tech to mostly medium-and-high-tech medical devices. Notably, foreign multinationals remain the leading suppliers of China’s high-tech medical device market. However, China’s advancement along the medical device GVC and increased domestic production of higher-tech medical devices may portend a reduced reliance on foreign producers.
BIBLIOGRAPHY

[https://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/our-insights/~/media/98d2e02830e84e0f9cbb330e622a64e1.ashx](https://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/our-insights/~/media/98d2e02830e84e0f9cbb330e622a64e1.ashx) (registration required).


China Climbs the Medical Device Global Value Chain


China Climbs the Medical Device Global Value Chain


